Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized cont... by Zhanyang Luo, Bukun Zhu, Hong Xu, Lixin Chen, Xiaoyun Song, Yu Wang, Rui Wang, Jinzhou Zheng, Yunhua Qiu, Jianfeng Yang, Youyang Shi

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status by Zhengquan Xu, Yanhong Ding, Wei Lu, Ke Zhang, Fei Wang, Guanxiong Ding, Jianqing Wang

Subjects: “…Metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer by Jeroen H. A. Creemers, Jeroen H. A. Creemers, Maarten J. van der Doelen, Maarten J. van der Doelen, Sandra van Wilpe, Sandra van Wilpe, Rick Hermsen, Tjitske Duiveman-de Boer, Diederik M. Somford, Marcel J. R. Janssen, J. P. Michiel Sedelaar, Niven Mehra, Niven Mehra, Johannes Textor, Johannes Textor, Harm Westdorp, Harm Westdorp

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA by Majid Assadi, Reyhaneh Manafi-Farid, Esmail Jafari, Ahmad Keshavarz, GhasemAli Divband, Mohammad Mobin Moradi, Zohreh Adinehpour, Rezvan Samimi, Habibollah Dadgar, Narges Jokar, Benjamin Mayer, Vikas Prasad

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer by Dan Su, Bin Wu, Lizheng Shi

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label,... by Ke Cheng, Yuqing Wang, Yuqing Wang, Ye Chen, Jingjie Zhu, Xiaohui Qi, Yachen Wang, Yanqiu Zou, Qiuhan Lu, Zhiping Li

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy by Manuel Neuberger, Christel Weiß, Nora Goly, Janina Skladny, Katja Nitschke, Frederik Wessels, Karl F. Kowalewski, Frank Waldbillig, Friedrich Hartung, Malin Nientiedt, Luisa Egen, Jonas Herrmann, Jonas Jarczyk, Margarete Teresa Walach, Maximilian C. Kriegmair, Niklas Westhoff, Thomas S. Worst, Philipp Nuhn

Subjects: “…Metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Whole-Body [¹⁸F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN... by Mark Muzi, Finbarr O’Sullivan, Timothy G. Perk, John P. Muzi, David A. Mankoff, Robert Jeraj, Fenghai Duan, Evan Y. Yu

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval by Amir Karimzadeh, Charlotte-Sophie Hecker, Matthias M. Heck, Robert Tauber, Calogero D’Alessandria, Wolfgang A. Weber, Matthias Eiber, Isabel Rauscher

Subjects: “…Metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians by Ting Bu, Lulu Zhang, Fei Yu, Xiaochen Yao, Wenyu Wu, Pengjun Zhang, Liang Shi, Shiming Zang, Qingle Meng, Yudan Ni, Guoqiang Shao, Xuefeng Qiu, Shuyue Ai, Ruipeng Jia, Hongqian Guo, Feng Wang

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report by Wei Ning, Pengkang Chang, Ji Zheng, Fan He, Fan He

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Advances in ¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer by Sui Wai Ling, Erik de Blois, Eline Hooijman, Astrid van der Veldt, Tessa Brabander

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report by Tsukasa Yoshida, Hiroshi Yaegashi, Ren Toriumi, Suguru Kadomoto, Hiroaki Iwamoto, Kouji Izumi, Yoshifumi Kadono, Hiroko Ikeda, Atsushi Mizokami

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-a... by Wenqiang Qi, Yongheng Zhou, Zhifeng Liu, Jian Wang, Guangda Lv, Minglei Zhong, Wenfu Wang, Rongyang Li, Shouzhen Chen, Benkang Shi, Yaofeng Zhu

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Rare histologic transformation of a CTNNB1 (β-catenin) mutated prostate cancer with aggressive clinical course by Dilara Akhoundova, Stefanie Fischer, Joanna Triscott, Marika Lehner, Phillip Thienger, Sina Maletti, Muriel Jacquet, Dinda S.H. Lubis, Lukas Bubendorf, Wolfram Jochum, Mark A. Rubin

Subjects: “…Metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China by Chenyang Xu, Xianzhi Zhao, Xiaoping Ju, Yuxin Shen, Min Qu, Yusheng Ye, Xiaoyan Wang, Chunshan Yu, Xu Gao, Huojun Zhang

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer by Yozo Mitsui, Fumito Yamabe, Shunsuke Hori, Masato Uetani, Hiroshi Aoki, Kei Sakurabayashi, Mizuho Okawa, Hideyuki Kobayashi, Koichi Nagao, Koichi Nakajima

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Editorial: Androgen-dependent diseases and their treatment by Marisa Cabeza

Subjects: “…metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Comparison of quantitative whole body PET parameters on [68Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconst... by Narjess Ayati, Lachlan McIntosh, James Buteau, Ramin Alipour, Michal Pudis, Nicholas Daw, Price Jackson, Michael S. Hofman

Subjects: “…Metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase II... by Joseph M. Unger, Katherine Griffin, Gary W. Donaldson, Karen M. Baranowski, Margorie J. Good, Eunicia Reburiano, Maha Hussain, Paul J. Monk, Peter J. Van Veldhuizen, Michael A. Carducci, Celestia S. Higano, Primo N. Lara, Catherine M. Tangen, David I. Quinn, James L. Wade, III, Nicholas J. Vogelzang, Ian M. Thompson, Jr, Carol M. Moinpour

Subjects: “…Metastatic castration-resistant prostate Cancer (mCRPC)…”
Get full text